科美诊断业绩快报：2025年净利润4440.76万元 同比下降65.05%

Core Viewpoint - Company reported a significant decline in revenue and net profit for the year 2025, primarily due to the impact of centralized procurement in the in vitro diagnostics industry [1] Financial Performance - Total operating revenue for 2025 was 333 million yuan, a year-on-year decrease of 23.75% [1] - Net profit attributable to shareholders was 44.41 million yuan, down 65.05% year-on-year [1] - Basic earnings per share stood at 0.11 yuan [1] Industry Impact - The in vitro diagnostics industry is experiencing price pressure on main products due to the deep implementation of centralized procurement nationwide [1] - The company's main business revenue has declined as a result of these industry-wide changes [1] Strategic Response - To enhance core competitiveness, the company has maintained a high level of investment in product innovation [1] - There has been a reduction in government subsidies and other non-recurring profit and loss items compared to the previous year [1]